| Category | Name | IntersectionWithQuery | PValue | GenesInTerm | GenesInQuery | GenesInTermInQuery | ID |
|---|---|---|---|---|---|---|---|
| GeneOntologyMolecularFunction | monocarboxylic acid transmembrane transporter activity | 9.51e-06 | 90 | 63 | 5 | GO:0008028 | |
| GeneOntologyMolecularFunction | granulocyte colony-stimulating factor receptor binding | 1.06e-05 | 14 | 63 | 3 | GO:0005130 | |
| GeneOntologyMolecularFunction | glycolipid binding | 1.71e-05 | 49 | 63 | 4 | GO:0051861 | |
| GeneOntologyMolecularFunction | organic anion transmembrane transporter activity | 3.74e-05 | 293 | 63 | 7 | GO:0008514 | |
| GeneOntologyMolecularFunction | carboxylic acid transmembrane transporter activity | 4.80e-05 | 207 | 63 | 6 | GO:0046943 | |
| GeneOntologyMolecularFunction | organic acid transmembrane transporter activity | 4.93e-05 | 208 | 63 | 6 | GO:0005342 | |
| GeneOntologyMolecularFunction | GPI anchor binding | 5.07e-05 | 23 | 63 | 3 | GO:0034235 | |
| GeneOntologyMolecularFunction | filamin binding | 1.03e-04 | 29 | 63 | 3 | GO:0031005 | |
| GeneOntologyMolecularFunction | Toll-like receptor binding | 1.03e-04 | 29 | 63 | 3 | GO:0035325 | |
| GeneOntologyMolecularFunction | gamma-aminobutyric acid:sodium:chloride symporter activity | 1.46e-04 | 6 | 63 | 2 | GO:0005332 | |
| GeneOntologyMolecularFunction | bile acid transmembrane transporter activity | 1.67e-04 | 34 | 63 | 3 | GO:0015125 | |
| GeneOntologyMolecularFunction | transmembrane transporter activity | CACNA1B SLC6A12 SLC6A13 PKD2L2 CLCA2 PSG1 SLC26A7 PSG4 TMEM150C PEX12 PSG8 SLC22A20P | 2.77e-04 | 1180 | 63 | 12 | GO:0022857 |
| GeneOntologyMolecularFunction | gamma-aminobutyric acid transmembrane transporter activity | 3.48e-04 | 9 | 63 | 2 | GO:0015185 | |
| GeneOntologyMolecularFunction | transporter activity | CACNA1B SLC6A12 SLC6A13 PKD2L2 CLCA2 PSG1 SLC26A7 PSG4 TMEM150C PEX12 PSG8 SLC22A20P | 6.15e-04 | 1289 | 63 | 12 | GO:0005215 |
| GeneOntologyMolecularFunction | chloride transmembrane transporter activity | 6.55e-04 | 125 | 63 | 4 | GO:0015108 | |
| GeneOntologyMolecularFunction | monocarboxylate:sodium symporter activity | 1.00e-03 | 15 | 63 | 2 | GO:0140161 | |
| GeneOntologyMolecularFunction | protein tyrosine kinase binding | 1.26e-03 | 149 | 63 | 4 | GO:1990782 | |
| GeneOntologyMolecularFunction | sodium:chloride symporter activity | 1.29e-03 | 17 | 63 | 2 | GO:0015378 | |
| GeneOntologyMolecularFunction | monoatomic anion transmembrane transporter activity | 1.32e-03 | 151 | 63 | 4 | GO:0008509 | |
| GeneOntologyMolecularFunction | organic hydroxy compound transmembrane transporter activity | 1.41e-03 | 70 | 63 | 3 | GO:1901618 | |
| GeneOntologyMolecularFunction | lipid transmembrane transporter activity | 1.59e-03 | 73 | 63 | 3 | GO:0170055 | |
| GeneOntologyMolecularFunction | secondary active monocarboxylate transmembrane transporter activity | 1.62e-03 | 19 | 63 | 2 | GO:0015355 | |
| GeneOntologyMolecularFunction | monoatomic anion:sodium symporter activity | 1.62e-03 | 19 | 63 | 2 | GO:0015373 | |
| GeneOntologyMolecularFunction | inorganic anion transmembrane transporter activity | 2.09e-03 | 171 | 63 | 4 | GO:0015103 | |
| GeneOntologyMolecularFunction | chloride:monoatomic cation symporter activity | 2.37e-03 | 23 | 63 | 2 | GO:0015377 | |
| GeneOntologyMolecularFunction | amino acid:sodium symporter activity | 2.37e-03 | 23 | 63 | 2 | GO:0005283 | |
| GeneOntologyMolecularFunction | monoatomic anion:monoatomic cation symporter activity | 3.03e-03 | 26 | 63 | 2 | GO:0015296 | |
| GeneOntologyMolecularFunction | amino acid:monoatomic cation symporter activity | 3.77e-03 | 29 | 63 | 2 | GO:0005416 | |
| GeneOntologyMolecularFunction | protein phosphatase binding | 4.36e-03 | 210 | 63 | 4 | GO:0019903 | |
| GeneOntologyMolecularFunction | receptor antagonist activity | 4.57e-03 | 32 | 63 | 2 | GO:0048019 | |
| GeneOntologyMolecularFunction | organic acid:sodium symporter activity | 5.45e-03 | 35 | 63 | 2 | GO:0005343 | |
| GeneOntologyMolecularFunction | calmodulin binding | 6.01e-03 | 230 | 63 | 4 | GO:0005516 | |
| GeneOntologyBiologicalProcess | monocarboxylic acid transport | 3.85e-06 | 213 | 63 | 7 | GO:0015718 | |
| GeneOntologyBiologicalProcess | regulation of platelet aggregation | 8.11e-06 | 42 | 63 | 4 | GO:0090330 | |
| GeneOntologyBiologicalProcess | platelet activation | 8.70e-06 | 158 | 63 | 6 | GO:0030168 | |
| GeneOntologyBiologicalProcess | negative regulation of brown fat cell proliferation | 9.65e-06 | 14 | 63 | 3 | GO:0070348 | |
| GeneOntologyBiologicalProcess | regulation of brown fat cell proliferation | 1.20e-05 | 15 | 63 | 3 | GO:0070347 | |
| GeneOntologyBiologicalProcess | positive regulation of homophilic cell adhesion | 1.20e-05 | 15 | 63 | 3 | GO:1903387 | |
| GeneOntologyBiologicalProcess | negative regulation of natural killer cell mediated immune response to tumor cell | 1.20e-05 | 15 | 63 | 3 | GO:0002856 | |
| GeneOntologyBiologicalProcess | negative regulation of natural killer cell mediated cytotoxicity directed against tumor cell target | 1.20e-05 | 15 | 63 | 3 | GO:0002859 | |
| GeneOntologyBiologicalProcess | blood coagulation | 1.41e-05 | 260 | 63 | 7 | GO:0007596 | |
| GeneOntologyBiologicalProcess | insulin receptor internalization | 1.48e-05 | 16 | 63 | 3 | GO:0038016 | |
| GeneOntologyBiologicalProcess | coagulation | 1.64e-05 | 266 | 63 | 7 | GO:0050817 | |
| GeneOntologyBiologicalProcess | hemostasis | 1.72e-05 | 268 | 63 | 7 | GO:0007599 | |
| GeneOntologyBiologicalProcess | brown fat cell proliferation | 1.79e-05 | 17 | 63 | 3 | GO:0070342 | |
| GeneOntologyBiologicalProcess | insulin catabolic process | 1.79e-05 | 17 | 63 | 3 | GO:1901143 | |
| GeneOntologyBiologicalProcess | granulocyte colony-stimulating factor signaling pathway | 1.79e-05 | 17 | 63 | 3 | GO:0038158 | |
| GeneOntologyBiologicalProcess | regulation of homotypic cell-cell adhesion | 2.07e-05 | 53 | 63 | 4 | GO:0034110 | |
| GeneOntologyBiologicalProcess | regulation of homophilic cell adhesion | 2.14e-05 | 18 | 63 | 3 | GO:1903385 | |
| GeneOntologyBiologicalProcess | negative regulation of hepatocyte proliferation | 2.98e-05 | 20 | 63 | 3 | GO:2000346 | |
| GeneOntologyBiologicalProcess | negative regulation of fat cell proliferation | 3.47e-05 | 21 | 63 | 3 | GO:0070345 | |
| GeneOntologyBiologicalProcess | negative regulation of response to tumor cell | 3.47e-05 | 21 | 63 | 3 | GO:0002835 | |
| GeneOntologyBiologicalProcess | negative regulation of immune response to tumor cell | 3.47e-05 | 21 | 63 | 3 | GO:0002838 | |
| GeneOntologyBiologicalProcess | regulation of feeding behavior | 3.62e-05 | 61 | 63 | 4 | GO:0060259 | |
| GeneOntologyBiologicalProcess | negative regulation of granulocyte differentiation | 4.01e-05 | 22 | 63 | 3 | GO:0030853 | |
| GeneOntologyBiologicalProcess | negative regulation of platelet aggregation | 4.60e-05 | 23 | 63 | 3 | GO:0090331 | |
| GeneOntologyBiologicalProcess | regulation of natural killer cell mediated cytotoxicity directed against tumor cell target | 4.60e-05 | 23 | 63 | 3 | GO:0002858 | |
| GeneOntologyBiologicalProcess | regulation of platelet activation | 4.94e-05 | 66 | 63 | 4 | GO:0010543 | |
| GeneOntologyBiologicalProcess | positive regulation of vasculogenesis | 5.25e-05 | 24 | 63 | 3 | GO:2001214 | |
| GeneOntologyBiologicalProcess | regulation of natural killer cell mediated immune response to tumor cell | 5.25e-05 | 24 | 63 | 3 | GO:0002855 | |
| GeneOntologyBiologicalProcess | natural killer cell mediated cytotoxicity directed against tumor cell target | 5.25e-05 | 24 | 63 | 3 | GO:0002420 | |
| GeneOntologyBiologicalProcess | gamma-aminobutyric acid reuptake | 5.49e-05 | 4 | 63 | 2 | GO:0051936 | |
| GeneOntologyBiologicalProcess | regulation of body fluid levels | 5.76e-05 | 442 | 63 | 8 | GO:0050878 | |
| GeneOntologyBiologicalProcess | common myeloid progenitor cell proliferation | 5.95e-05 | 25 | 63 | 3 | GO:0035726 | |
| GeneOntologyBiologicalProcess | natural killer cell mediated immune response to tumor cell | 5.95e-05 | 25 | 63 | 3 | GO:0002423 | |
| GeneOntologyBiologicalProcess | response to tumor cell | 6.59e-05 | 71 | 63 | 4 | GO:0002347 | |
| GeneOntologyBiologicalProcess | negative regulation of interleukin-1 production | 6.96e-05 | 72 | 63 | 4 | GO:0032692 | |
| GeneOntologyBiologicalProcess | regulation of fat cell proliferation | 7.54e-05 | 27 | 63 | 3 | GO:0070344 | |
| GeneOntologyBiologicalProcess | negative regulation of homotypic cell-cell adhesion | 8.42e-05 | 28 | 63 | 3 | GO:0034111 | |
| GeneOntologyBiologicalProcess | gamma-aminobutyric acid transport | 8.42e-05 | 28 | 63 | 3 | GO:0015812 | |
| GeneOntologyBiologicalProcess | regulation of vasculogenesis | 9.38e-05 | 29 | 63 | 3 | GO:2001212 | |
| GeneOntologyBiologicalProcess | negative regulation of platelet activation | 1.15e-04 | 31 | 63 | 3 | GO:0010544 | |
| GeneOntologyBiologicalProcess | negative regulation of lymphocyte mediated immunity | 1.21e-04 | 83 | 63 | 4 | GO:0002707 | |
| GeneOntologyBiologicalProcess | wound healing | 1.23e-04 | 493 | 63 | 8 | GO:0042060 | |
| GeneOntologyBiologicalProcess | negative regulation of bone resorption | 1.26e-04 | 32 | 63 | 3 | GO:0045779 | |
| GeneOntologyBiologicalProcess | fat cell proliferation | 1.26e-04 | 32 | 63 | 3 | GO:0070341 | |
| GeneOntologyBiologicalProcess | regulation of blood vessel remodeling | 1.26e-04 | 32 | 63 | 3 | GO:0060312 | |
| GeneOntologyBiologicalProcess | feeding behavior | 1.37e-04 | 162 | 63 | 5 | GO:0007631 | |
| GeneOntologyBiologicalProcess | regulation of granulocyte differentiation | 1.39e-04 | 33 | 63 | 3 | GO:0030852 | |
| GeneOntologyBiologicalProcess | negative regulation of feeding behavior | 1.39e-04 | 33 | 63 | 3 | GO:2000252 | |
| GeneOntologyBiologicalProcess | negative regulation of vascular permeability | 1.52e-04 | 34 | 63 | 3 | GO:0043116 | |
| GeneOntologyBiologicalProcess | negative regulation of bone remodeling | 1.52e-04 | 34 | 63 | 3 | GO:0046851 | |
| GeneOntologyBiologicalProcess | regulation of wound healing | 1.53e-04 | 166 | 63 | 5 | GO:0061041 | |
| GeneOntologyBiologicalProcess | insulin metabolic process | 1.66e-04 | 35 | 63 | 3 | GO:1901142 | |
| GeneOntologyBiologicalProcess | organic anion transport | 1.66e-04 | 515 | 63 | 8 | GO:0015711 | |
| GeneOntologyBiologicalProcess | regulation of blood coagulation | 1.73e-04 | 91 | 63 | 4 | GO:0030193 | |
| GeneOntologyBiologicalProcess | regulation of hemostasis | 1.88e-04 | 93 | 63 | 4 | GO:1900046 | |
| GeneOntologyBiologicalProcess | platelet aggregation | 2.04e-04 | 95 | 63 | 4 | GO:0070527 | |
| GeneOntologyBiologicalProcess | gland morphogenesis | 2.12e-04 | 178 | 63 | 5 | GO:0022612 | |
| GeneOntologyBiologicalProcess | regulation of hepatocyte proliferation | 2.12e-04 | 38 | 63 | 3 | GO:2000345 | |
| GeneOntologyBiologicalProcess | negative regulation of leukocyte mediated immunity | 2.13e-04 | 96 | 63 | 4 | GO:0002704 | |
| GeneOntologyBiologicalProcess | regulation of coagulation | 2.13e-04 | 96 | 63 | 4 | GO:0050818 | |
| GeneOntologyBiologicalProcess | negative regulation of fatty acid biosynthetic process | 2.29e-04 | 39 | 63 | 3 | GO:0045717 | |
| GeneOntologyBiologicalProcess | carboxylic acid transport | 2.47e-04 | 410 | 63 | 7 | GO:0046942 | |
| GeneOntologyBiologicalProcess | negative regulation of natural killer cell mediated cytotoxicity | 2.48e-04 | 40 | 63 | 3 | GO:0045953 | |
| GeneOntologyBiologicalProcess | organic acid transport | 2.55e-04 | 412 | 63 | 7 | GO:0015849 | |
| GeneOntologyBiologicalProcess | negative regulation of natural killer cell mediated immunity | 2.66e-04 | 41 | 63 | 3 | GO:0002716 | |
| GeneOntologyBiologicalProcess | regulation of small molecule metabolic process | 3.49e-04 | 434 | 63 | 7 | GO:0062012 | |
| GeneOntologyBiologicalProcess | negative regulation of behavior | 3.52e-04 | 45 | 63 | 3 | GO:0048521 | |
| GeneOntologyBiologicalProcess | epithelial cell proliferation involved in liver morphogenesis | 3.75e-04 | 46 | 63 | 3 | GO:0072575 | |
| GeneOntologyBiologicalProcess | hepatocyte proliferation | 3.75e-04 | 46 | 63 | 3 | GO:0072574 | |
| GeneOntologyBiologicalProcess | negative regulation of leukocyte mediated cytotoxicity | 4.00e-04 | 47 | 63 | 3 | GO:0001911 | |
| GeneOntologyBiologicalProcess | bile acid and bile salt transport | 4.00e-04 | 47 | 63 | 3 | GO:0015721 | |
| GeneOntologyBiologicalProcess | negative regulation of tissue remodeling | 4.00e-04 | 47 | 63 | 3 | GO:0034104 | |
| GeneOntologyBiologicalProcess | amino acid neurotransmitter reuptake | 4.07e-04 | 10 | 63 | 2 | GO:0051933 | |
| GeneOntologyBiologicalProcess | negative regulation of innate immune response | 4.10e-04 | 114 | 63 | 4 | GO:0045824 | |
| GeneOntologyBiologicalProcess | liver morphogenesis | 4.53e-04 | 49 | 63 | 3 | GO:0072576 | |
| GeneOntologyBiologicalProcess | regulation of immune response to tumor cell | 4.53e-04 | 49 | 63 | 3 | GO:0002837 | |
| GeneOntologyBiologicalProcess | vasculogenesis | 4.67e-04 | 118 | 63 | 4 | GO:0001570 | |
| GeneOntologyBiologicalProcess | regulation of response to tumor cell | 4.80e-04 | 50 | 63 | 3 | GO:0002834 | |
| GeneOntologyBiologicalProcess | regulation of response to wounding | 5.27e-04 | 217 | 63 | 5 | GO:1903034 | |
| GeneOntologyBiologicalProcess | negative regulation of cell killing | 5.39e-04 | 52 | 63 | 3 | GO:0031342 | |
| GeneOntologyBiologicalProcess | homotypic cell-cell adhesion | 5.64e-04 | 124 | 63 | 4 | GO:0034109 | |
| GeneOntologyBiologicalProcess | action potential propagation | 5.94e-04 | 12 | 63 | 2 | GO:0098870 | |
| GeneOntologyBiologicalProcess | neuronal action potential propagation | 5.94e-04 | 12 | 63 | 2 | GO:0019227 | |
| GeneOntologyBiologicalProcess | regulation of behavior | 6.35e-04 | 128 | 63 | 4 | GO:0050795 | |
| GeneOntologyBiologicalProcess | immune response to tumor cell | 6.71e-04 | 56 | 63 | 3 | GO:0002418 | |
| GeneOntologyBiologicalProcess | regulation of fatty acid metabolic process | 7.54e-04 | 134 | 63 | 4 | GO:0019217 | |
| GeneOntologyBiologicalProcess | negative regulation of osteoclast differentiation | 7.81e-04 | 59 | 63 | 3 | GO:0045671 | |
| GeneOntologyBiologicalProcess | monoatomic ion transport | CACNA1B SLC6A12 SLC6A13 SPHK2 PKD2L2 CLCA2 P2RY1 SLC26A7 NTSR1 TMEM150C SLC22A20P OPRK1 | 8.13e-04 | 1374 | 63 | 12 | GO:0006811 |
| GeneOntologyBiologicalProcess | negative regulation of immune response | 8.15e-04 | 239 | 63 | 5 | GO:0050777 | |
| GeneOntologyBiologicalProcess | granulocyte differentiation | 8.21e-04 | 60 | 63 | 3 | GO:0030851 | |
| GeneOntologyBiologicalProcess | negative regulation of fatty acid metabolic process | 8.21e-04 | 60 | 63 | 3 | GO:0045922 | |
| GeneOntologyBiologicalProcess | response to wounding | 8.56e-04 | 659 | 63 | 8 | GO:0009611 | |
| GeneOntologyBiologicalProcess | regulation of lipid biosynthetic process | 9.27e-04 | 246 | 63 | 5 | GO:0046890 | |
| GeneOntologyBiologicalProcess | cell-cell junction organization | 9.27e-04 | 246 | 63 | 5 | GO:0045216 | |
| GeneOntologyBiologicalProcess | energy homeostasis | 9.86e-04 | 144 | 63 | 4 | GO:0097009 | |
| GeneOntologyBiologicalProcess | small molecule biosynthetic process | 1.01e-03 | 676 | 63 | 8 | GO:0044283 | |
| GeneOntologyBiologicalProcess | positive regulation of inositol phosphate biosynthetic process | 1.07e-03 | 16 | 63 | 2 | GO:0060732 | |
| GeneOntologyBiologicalProcess | negative regulation of small molecule metabolic process | 1.12e-03 | 149 | 63 | 4 | GO:0062014 | |
| GeneOntologyBiologicalProcess | regulation of endothelial cell differentiation | 1.13e-03 | 67 | 63 | 3 | GO:0045601 | |
| GeneOntologyBiologicalProcess | negative regulation of leukocyte differentiation | 1.18e-03 | 151 | 63 | 4 | GO:1902106 | |
| GeneOntologyCellularComponent | basal plasma membrane | 9.53e-06 | 354 | 62 | 8 | GO:0009925 | |
| GeneOntologyCellularComponent | transforming growth factor beta ligand-receptor complex | 1.35e-05 | 16 | 62 | 3 | GO:0070021 | |
| GeneOntologyCellularComponent | basal part of cell | 1.53e-05 | 378 | 62 | 8 | GO:0045178 | |
| GeneOntologyCellularComponent | basolateral plasma membrane | 4.41e-05 | 320 | 62 | 7 | GO:0016323 | |
| GeneOntologyCellularComponent | lateral plasma membrane | 1.48e-04 | 90 | 62 | 4 | GO:0016328 | |
| GeneOntologyCellularComponent | T cell receptor complex | 1.40e-03 | 163 | 62 | 4 | GO:0042101 | |
| GeneOntologyCellularComponent | cell surface | 1.49e-03 | 1111 | 62 | 10 | GO:0009986 | |
| MousePheno | decreased susceptibility to Coronaviridae infection induced morbidity/mortality | 2.50e-05 | 17 | 48 | 3 | MP:0031047 | |
| MousePheno | decreased chemically-elicited antinociception | 3.54e-05 | 19 | 48 | 3 | MP:0001982 | |
| MousePheno | increased skeletal muscle triglyceride level | 4.84e-05 | 21 | 48 | 3 | MP:0031415 | |
| MousePheno | decreased activity of thyroid gland | 4.84e-05 | 21 | 48 | 3 | MP:0003503 | |
| MousePheno | decreased fatty acid oxidation | 7.31e-05 | 24 | 48 | 3 | MP:0014172 | |
| MousePheno | abnormal carbon dioxide production | 8.00e-05 | 67 | 48 | 4 | MP:0008962 | |
| MousePheno | increased abdominal fat pad weight | 1.05e-04 | 27 | 48 | 3 | MP:0009286 | |
| MousePheno | abnormal node of Ranvier morphology | 1.15e-04 | 5 | 48 | 2 | MP:0010732 | |
| MousePheno | decreased susceptibility to Coronaviridae infection | 1.17e-04 | 28 | 48 | 3 | MP:0020950 | |
| MousePheno | abnormal chemically-elicited antinociception | 1.30e-04 | 29 | 48 | 3 | MP:0001980 | |
| MousePheno | abnormal thyroid gland physiology | 1.45e-04 | 30 | 48 | 3 | MP:0002876 | |
| MousePheno | decreased oxygen consumption | 1.52e-04 | 79 | 48 | 4 | MP:0005290 | |
| MousePheno | abnormal skeletal muscle triglyceride level | 1.60e-04 | 31 | 48 | 3 | MP:0031413 | |
| MousePheno | decreased carbon dioxide production | 1.60e-04 | 31 | 48 | 3 | MP:0008964 | |
| MousePheno | polyphagia | 1.60e-04 | 80 | 48 | 4 | MP:0001433 | |
| MousePheno | abnormal thyroid-stimulating hormone level | 1.93e-04 | 33 | 48 | 3 | MP:0003971 | |
| MousePheno | decreased skeletal muscle cell glucose uptake | 2.30e-04 | 35 | 48 | 3 | MP:0031618 | |
| MousePheno | abnormal muscle triglyceride level | 2.51e-04 | 36 | 48 | 3 | MP:0031412 | |
| MousePheno | decreased muscle cell glucose uptake | 3.18e-04 | 39 | 48 | 3 | MP:0030022 | |
| MousePheno | decreased circulating levels of thyroid hormone | 4.26e-04 | 43 | 48 | 3 | MP:0003351 | |
| MousePheno | decreased susceptibility to Riboviria infection induced morbidity/mortality | 4.56e-04 | 44 | 48 | 3 | MP:0031023 | |
| MousePheno | abnormal oxygen consumption | 5.28e-04 | 195 | 48 | 5 | MP:0005288 | |
| MousePheno | decreased respiratory quotient | 5.41e-04 | 110 | 48 | 4 | MP:0010379 | |
| MousePheno | abnormal skeletal muscle cell glucose uptake | 5.54e-04 | 47 | 48 | 3 | MP:0031617 | |
| MousePheno | abnormal susceptibility to Coronaviridae infection | 6.27e-04 | 49 | 48 | 3 | MP:0020948 | |
| MousePheno | abnormal energy expenditure | 6.68e-04 | 313 | 48 | 6 | MP:0005450 | |
| MousePheno | abnormal fat pad morphology | 6.79e-04 | 314 | 48 | 6 | MP:0005334 | |
| MousePheno | disorganized secondary lens fibers | 7.45e-04 | 12 | 48 | 2 | MP:0002579 | |
| MousePheno | abnormal energy homeostasis | 7.74e-04 | 322 | 48 | 6 | MP:0005448 | |
| MousePheno | decreased cellular glucose uptake | 7.89e-04 | 53 | 48 | 3 | MP:0003926 | |
| MousePheno | abnormal fatty acid oxidation | 8.33e-04 | 54 | 48 | 3 | MP:0010953 | |
| MousePheno | decreased susceptibility to viral infection induced morbidity/mortality | 1.13e-03 | 60 | 48 | 3 | MP:0009790 | |
| MousePheno | abnormal lipid oxidation | 1.19e-03 | 61 | 48 | 3 | MP:0010951 | |
| MousePheno | decreased platelet aggregation | 1.25e-03 | 62 | 48 | 3 | MP:0009549 | |
| MousePheno | increased insulin secretion | 1.37e-03 | 64 | 48 | 3 | MP:0003058 | |
| MousePheno | increased incidence of tumors by chemical induction | 1.37e-03 | 141 | 48 | 4 | MP:0004499 | |
| MousePheno | abnormal endocrine gland physiology | 1.44e-03 | 363 | 48 | 6 | MP:0013561 | |
| MousePheno | abnormal glycogen homeostasis | 1.48e-03 | 144 | 48 | 4 | MP:0005438 | |
| MousePheno | increased circulating thyroid-stimulating hormone level | 1.52e-03 | 17 | 48 | 2 | MP:0005122 | |
| MousePheno | abnormal muscle cell glucose uptake | 1.56e-03 | 67 | 48 | 3 | MP:0004130 | |
| MousePheno | decreased circulating triiodothyronine level | 1.71e-03 | 18 | 48 | 2 | MP:0005479 | |
| Domain | Ig_2 | 4.32e-06 | 73 | 62 | 5 | PF13895 | |
| Domain | - | 1.08e-05 | 2 | 62 | 2 | 3.40.630.20 | |
| Domain | Peptidase_C15 | 1.08e-05 | 2 | 62 | 2 | IPR000816 | |
| Domain | Peptidase_C15-like | 1.08e-05 | 2 | 62 | 2 | IPR016125 | |
| Domain | Peptidase_C15 | 1.08e-05 | 2 | 62 | 2 | PF01470 | |
| Domain | PYRASE_CYS | 1.08e-05 | 2 | 62 | 2 | PS01334 | |
| Domain | PYRASE_GLU | 1.08e-05 | 2 | 62 | 2 | PS01333 | |
| Domain | IGc2 | 1.25e-05 | 235 | 62 | 7 | SM00408 | |
| Domain | Ig_sub2 | 1.25e-05 | 235 | 62 | 7 | IPR003598 | |
| Domain | ig | 3.92e-05 | 190 | 62 | 6 | PF00047 | |
| Domain | Immunoglobulin | 3.92e-05 | 190 | 62 | 6 | IPR013151 | |
| Domain | IG | 7.27e-05 | 421 | 62 | 8 | SM00409 | |
| Domain | Ig_sub | 7.27e-05 | 421 | 62 | 8 | IPR003599 | |
| Domain | IG_LIKE | 2.10e-04 | 491 | 62 | 8 | PS50835 | |
| Domain | Ig-like_dom | 2.47e-04 | 503 | 62 | 8 | IPR007110 | |
| Domain | - | 3.20e-04 | 663 | 62 | 9 | 2.60.40.10 | |
| Domain | Ig-like_fold | 5.05e-04 | 706 | 62 | 9 | IPR013783 | |
| Domain | TIL | 7.00e-04 | 12 | 62 | 2 | PF01826 | |
| Domain | C8 | 7.00e-04 | 12 | 62 | 2 | PF08742 | |
| Domain | Unchr_dom_Cys-rich | 8.26e-04 | 13 | 62 | 2 | IPR014853 | |
| Domain | C8 | 8.26e-04 | 13 | 62 | 2 | SM00832 | |
| Domain | TIL_dom | 9.62e-04 | 14 | 62 | 2 | IPR002919 | |
| Domain | VWD | 1.26e-03 | 16 | 62 | 2 | SM00216 | |
| Domain | VWF_type-D | 1.26e-03 | 16 | 62 | 2 | IPR001846 | |
| Domain | VWFD | 1.26e-03 | 16 | 62 | 2 | PS51233 | |
| Domain | VWD | 1.26e-03 | 16 | 62 | 2 | PF00094 | |
| Domain | NA_NEUROTRAN_SYMP_2 | 1.60e-03 | 18 | 62 | 2 | PS00754 | |
| Domain | CTCK_1 | 1.60e-03 | 18 | 62 | 2 | PS01185 | |
| Domain | VWC_out | 1.79e-03 | 19 | 62 | 2 | SM00215 | |
| Domain | SNF | 1.79e-03 | 19 | 62 | 2 | PF00209 | |
| Domain | NA_NEUROTRAN_SYMP_1 | 1.79e-03 | 19 | 62 | 2 | PS00610 | |
| Domain | NA_NEUROTRAN_SYMP_3 | 1.79e-03 | 19 | 62 | 2 | PS50267 | |
| Domain | Na/ntran_symport | 1.79e-03 | 19 | 62 | 2 | IPR000175 | |
| Domain | CT | 2.40e-03 | 22 | 62 | 2 | SM00041 | |
| Domain | Cys_knot_C | 3.10e-03 | 25 | 62 | 2 | IPR006207 | |
| Domain | CTCK_2 | 3.10e-03 | 25 | 62 | 2 | PS01225 | |
| Domain | V-set | 3.26e-03 | 184 | 62 | 4 | PF07686 | |
| Domain | VWC | 3.88e-03 | 28 | 62 | 2 | PF00093 | |
| Domain | Ig_V-set | 4.31e-03 | 199 | 62 | 4 | IPR013106 | |
| Domain | VWFC_1 | 6.35e-03 | 36 | 62 | 2 | PS01208 | |
| Domain | VWC | 7.06e-03 | 38 | 62 | 2 | SM00214 | |
| Domain | VWFC_2 | 7.06e-03 | 38 | 62 | 2 | PS50184 | |
| Domain | LAM_G_DOMAIN | 7.06e-03 | 38 | 62 | 2 | PS50025 | |
| Domain | Laminin_G_2 | 7.80e-03 | 40 | 62 | 2 | PF02210 | |
| Domain | VWF_dom | 8.57e-03 | 42 | 62 | 2 | IPR001007 | |
| Pubmed | 1.75e-08 | 16 | 63 | 4 | 25085348 | ||
| Pubmed | Prospective isolation and global gene expression analysis of definitive and visceral endoderm. | 1.51e-06 | 46 | 63 | 4 | 17328885 | |
| Pubmed | Regulation of hepatic fibrosis by carcinoembryonic antigen-related cell adhesion molecule 1. | 1.60e-06 | 13 | 63 | 3 | 34058224 | |
| Pubmed | A mouse carcinoembryonic antigen gene family member is a calcium-dependent cell adhesion molecule. | 1.60e-06 | 13 | 63 | 3 | 1985902 | |
| Pubmed | 1.60e-06 | 13 | 63 | 3 | 10964771 | ||
| Pubmed | 1.60e-06 | 13 | 63 | 3 | 32169849 | ||
| Pubmed | CEACAM1+ myeloid cells control angiogenesis in inflammation. | 1.60e-06 | 13 | 63 | 3 | 19273835 | |
| Pubmed | Mechanism of glucose intolerance in mice with dominant negative mutation of CEACAM1. | 1.60e-06 | 13 | 63 | 3 | 16638824 | |
| Pubmed | 1.60e-06 | 13 | 63 | 3 | 20044046 | ||
| Pubmed | 1.60e-06 | 13 | 63 | 3 | 32150576 | ||
| Pubmed | 1.60e-06 | 13 | 63 | 3 | 22469976 | ||
| Pubmed | 1.60e-06 | 13 | 63 | 3 | 6265583 | ||
| Pubmed | CEACAM1 creates a pro-angiogenic tumor microenvironment that supports tumor vessel maturation. | 1.60e-06 | 13 | 63 | 3 | 21532628 | |
| Pubmed | Structural and Molecular Evidence Suggesting Coronavirus-driven Evolution of Mouse Receptor. | 1.60e-06 | 13 | 63 | 3 | 28035001 | |
| Pubmed | 1.60e-06 | 13 | 63 | 3 | 34440862 | ||
| Pubmed | CEACAM1 is a potent regulator of B cell receptor complex-induced activation. | 1.60e-06 | 13 | 63 | 3 | 12832451 | |
| Pubmed | 1.60e-06 | 13 | 63 | 3 | 25406283 | ||
| Pubmed | Interaction between altered insulin and lipid metabolism in CEACAM1-inactive transgenic mice. | 1.60e-06 | 13 | 63 | 3 | 15316023 | |
| Pubmed | Crystal structure of mouse coronavirus receptor-binding domain complexed with its murine receptor. | 1.60e-06 | 13 | 63 | 3 | 21670291 | |
| Pubmed | 1.60e-06 | 13 | 63 | 3 | 22162753 | ||
| Pubmed | In vivo adaptation and persistence of Neisseria meningitidis within the nasopharyngeal mucosa. | 1.60e-06 | 13 | 63 | 3 | 23935487 | |
| Pubmed | 1.60e-06 | 13 | 63 | 3 | 2702644 | ||
| Pubmed | 1.60e-06 | 13 | 63 | 3 | 8380065 | ||
| Pubmed | 1.60e-06 | 13 | 63 | 3 | 1279194 | ||
| Pubmed | 1.60e-06 | 13 | 63 | 3 | 15331748 | ||
| Pubmed | 1.60e-06 | 13 | 63 | 3 | 22673933 | ||
| Pubmed | Tumor angiogenesis mediated by myeloid cells is negatively regulated by CEACAM1. | 1.60e-06 | 13 | 63 | 3 | 22406619 | |
| Pubmed | 1.60e-06 | 13 | 63 | 3 | 7628460 | ||
| Pubmed | 1.60e-06 | 13 | 63 | 3 | 25724769 | ||
| Pubmed | 1.60e-06 | 13 | 63 | 3 | 26374765 | ||
| Pubmed | Forced Hepatic Overexpression of CEACAM1 Curtails Diet-Induced Insulin Resistance. | 1.60e-06 | 13 | 63 | 3 | 25972571 | |
| Pubmed | CEACAM1 deficiency delays important wound healing processes. | 1.60e-06 | 13 | 63 | 3 | 22092845 | |
| Pubmed | 1.60e-06 | 13 | 63 | 3 | 11801635 | ||
| Pubmed | 1.60e-06 | 13 | 63 | 3 | 28913658 | ||
| Pubmed | 1.60e-06 | 13 | 63 | 3 | 19008452 | ||
| Pubmed | 1.60e-06 | 13 | 63 | 3 | 18544705 | ||
| Pubmed | Expression of the mouse hepatitis virus receptor by central nervous system microglia. | 1.60e-06 | 13 | 63 | 3 | 15220458 | |
| Pubmed | Expression of the Bgp gene and characterization of mouse colon biliary glycoprotein isoforms. | 1.60e-06 | 13 | 63 | 3 | 8500759 | |
| Pubmed | 1.60e-06 | 13 | 63 | 3 | 18843289 | ||
| Pubmed | Mouse susceptibility to mouse hepatitis virus infection is linked to viral receptor genotype. | 1.60e-06 | 13 | 63 | 3 | 9343248 | |
| Pubmed | Ceacam1 deletion causes vascular alterations in large vessels. | 1.60e-06 | 13 | 63 | 3 | 23800882 | |
| Pubmed | 1.60e-06 | 13 | 63 | 3 | 15207636 | ||
| Pubmed | 1.60e-06 | 13 | 63 | 3 | 19285068 | ||
| Pubmed | 1.60e-06 | 13 | 63 | 3 | 21760897 | ||
| Pubmed | 1.60e-06 | 13 | 63 | 3 | 1719235 | ||
| Pubmed | Mouse hepatitis virus utilizes two carcinoembryonic antigens as alternative receptors. | 1.60e-06 | 13 | 63 | 3 | 1326665 | |
| Pubmed | 1.60e-06 | 13 | 63 | 3 | 21081647 | ||
| Pubmed | 1.60e-06 | 13 | 63 | 3 | 11133662 | ||
| Pubmed | Conditional deletion of CEACAM1 in hepatic stellate cells causes their activation. | 1.60e-06 | 13 | 63 | 3 | 39168268 | |
| Pubmed | 1.60e-06 | 13 | 63 | 3 | 11483763 | ||
| Pubmed | 1.60e-06 | 13 | 63 | 3 | 8402684 | ||
| Pubmed | 1.60e-06 | 13 | 63 | 3 | 2164599 | ||
| Pubmed | 1.60e-06 | 13 | 63 | 3 | 16619040 | ||
| Pubmed | 1.60e-06 | 13 | 63 | 3 | 29377208 | ||
| Pubmed | Expression of MHV-A59 receptor glycoproteins in susceptible and resistant strains of mice. | 1.60e-06 | 13 | 63 | 3 | 8209741 | |
| Pubmed | 1.60e-06 | 13 | 63 | 3 | 27002145 | ||
| Pubmed | Mice with null mutation of Ceacam I develop nonalcoholic steatohepatitis. | 1.60e-06 | 13 | 63 | 3 | 21949477 | |
| Pubmed | 1.60e-06 | 13 | 63 | 3 | 29396368 | ||
| Pubmed | 1.60e-06 | 13 | 63 | 3 | 26219866 | ||
| Pubmed | 1.60e-06 | 13 | 63 | 3 | 18003729 | ||
| Pubmed | 1.60e-06 | 13 | 63 | 3 | 26284027 | ||
| Pubmed | 1.60e-06 | 13 | 63 | 3 | 2133556 | ||
| Pubmed | 1.60e-06 | 13 | 63 | 3 | 32521208 | ||
| Pubmed | CEACAM1 specifically suppresses B cell receptor signaling-mediated activation. | 1.60e-06 | 13 | 63 | 3 | 33352461 | |
| Pubmed | 1.60e-06 | 13 | 63 | 3 | 19406938 | ||
| Pubmed | 1.60e-06 | 13 | 63 | 3 | 38381498 | ||
| Pubmed | 1.60e-06 | 13 | 63 | 3 | 20739537 | ||
| Pubmed | 1.60e-06 | 13 | 63 | 3 | 19621080 | ||
| Pubmed | CEACAM1 promotes CD8+ T cell responses and improves control of a chronic viral infection. | 1.60e-06 | 13 | 63 | 3 | 29967450 | |
| Pubmed | 1.60e-06 | 13 | 63 | 3 | 1633107 | ||
| Pubmed | Expression of newly identified secretory CEACAM1(a) isoforms in the intestinal epithelium. | 1.60e-06 | 13 | 63 | 3 | 19358828 | |
| Pubmed | The role of CEA-related cell adhesion molecule-1 (CEACAM1) in vascular homeostasis. | 1.60e-06 | 13 | 63 | 3 | 27695943 | |
| Pubmed | 1.60e-06 | 13 | 63 | 3 | 20404914 | ||
| Pubmed | 1.60e-06 | 13 | 63 | 3 | 16680193 | ||
| Pubmed | 1.60e-06 | 13 | 63 | 3 | 26911181 | ||
| Pubmed | 1.60e-06 | 13 | 63 | 3 | 1653760 | ||
| Pubmed | Hepatic CEACAM1 expression indicates donor liver quality and prevents early transplantation injury. | 1.60e-06 | 13 | 63 | 3 | 32027621 | |
| Pubmed | 1.60e-06 | 13 | 63 | 3 | 30664851 | ||
| Pubmed | Role for hepatic CEACAM1 in regulating fatty acid metabolism along the adipocyte-hepatocyte axis. | 1.60e-06 | 13 | 63 | 3 | 27777319 | |
| Pubmed | 1.60e-06 | 13 | 63 | 3 | 18848945 | ||
| Pubmed | 2.03e-06 | 14 | 63 | 3 | 37531413 | ||
| Pubmed | 2.03e-06 | 14 | 63 | 3 | 23780386 | ||
| Pubmed | 2.03e-06 | 14 | 63 | 3 | 28567513 | ||
| Pubmed | 2.03e-06 | 14 | 63 | 3 | 8207827 | ||
| Pubmed | Human CEACAM1-LF regulates lipid storage in HepG2 cells via fatty acid transporter CD36. | 2.03e-06 | 14 | 63 | 3 | 34666041 | |
| Pubmed | 2.03e-06 | 14 | 63 | 3 | 19700760 | ||
| Pubmed | 2.03e-06 | 14 | 63 | 3 | 34619794 | ||
| Pubmed | Expression patterns of CD66a and CD117 in the mouse submandibular gland. | 2.03e-06 | 14 | 63 | 3 | 25498293 | |
| Pubmed | Endothelial barrier function is differentially regulated by CEACAM1-mediated signaling. | 2.03e-06 | 14 | 63 | 3 | 29746166 | |
| Pubmed | 2.03e-06 | 14 | 63 | 3 | 9212243 | ||
| Pubmed | CEACAM1 controls the EMT switch in murine mammary carcinoma in vitro and in vivo. | 2.03e-06 | 14 | 63 | 3 | 27572314 | |
| Pubmed | 2.03e-06 | 14 | 63 | 3 | 1648219 | ||
| Pubmed | SHP1 phosphatase-dependent T cell inhibition by CEACAM1 adhesion molecule isoforms. | 2.03e-06 | 14 | 63 | 3 | 17081782 | |
| Pubmed | Loss of Ceacam1 promotes prostate cancer progression in Pten haploinsufficient male mice. | 2.03e-06 | 14 | 63 | 3 | 32209360 | |
| Pubmed | 2.03e-06 | 14 | 63 | 3 | 11994468 | ||
| Pubmed | 2.03e-06 | 14 | 63 | 3 | 11850617 | ||
| Pubmed | CEACAM2 positively regulates integrin αIIbβ3-mediated platelet functions. | 2.03e-06 | 14 | 63 | 3 | 27161904 | |
| Pubmed | 2.03e-06 | 14 | 63 | 3 | 20381490 | ||
| Pubmed | CEACAM1 regulates integrin αIIbβ3-mediated functions in platelets. | 2.03e-06 | 14 | 63 | 3 | 26196244 | |
| Pubmed | 2.03e-06 | 14 | 63 | 3 | 8896983 | ||
| Interaction | PSG8 interactions | 1.61e-07 | 41 | 62 | 5 | int:PSG8 | |
| Interaction | PSG4 interactions | 1.54e-06 | 8 | 62 | 3 | int:PSG4 | |
| Interaction | PSG3 interactions | 4.10e-05 | 22 | 62 | 3 | int:PSG3 | |
| Cytoband | 12p13.3 | 9.74e-06 | 30 | 63 | 3 | 12p13.3 | |
| Cytoband | 19q13.2 | 7.93e-05 | 164 | 63 | 4 | 19q13.2 | |
| Cytoband | Ensembl 112 genes in cytogenetic band chr12p13 | 1.43e-03 | 353 | 63 | 4 | chr12p13 | |
| Cytoband | 9q34 | 2.53e-03 | 54 | 63 | 2 | 9q34 | |
| GeneFamily | CD molecules|V-set domain containing|Pregnancy specific glycoproteins | 2.19e-06 | 11 | 44 | 3 | 1315 | |
| GeneFamily | Adenosine receptors|V-set domain containing | 6.53e-04 | 163 | 44 | 4 | 590 | |
| Coexpression | GIBBONS_GENETIC_MOUSE_MODEL_LUNG_ADENOCARCINOMA_DOWN_IN_METASTASIS | 1.04e-06 | 32 | 63 | 4 | MM2 | |
| Coexpression | WANG_RESPONSE_TO_BEXAROTENE_UP | 5.45e-06 | 48 | 63 | 4 | MM531 | |
| Coexpression | GSE19888_CTRL_VS_A3R_ACT_TREATED_MAST_CELL_PRETREATED_WITH_A3R_INH_UP | 8.42e-06 | 199 | 63 | 6 | M7329 | |
| Coexpression | BOYLAN_MULTIPLE_MYELOMA_PCA3_DN | 5.81e-05 | 87 | 63 | 4 | MM851 | |
| Coexpression | DESCARTES_FETAL_PLACENTA_TROPHOBLAST_GIANT_CELLS | 7.54e-05 | 93 | 63 | 4 | M40279 | |
| Coexpression | OUYANG_PROSTATE_CANCER_MARKERS | 8.20e-05 | 35 | 63 | 3 | MM757 | |
| Drug | Cefalonium [5575-21-3]; Up 200; 8.8uM; HL60; HT_HG-U133A | 1.28e-06 | 199 | 63 | 7 | 2921_UP | |
| Drug | Rgd Peptide | 4.32e-06 | 239 | 63 | 7 | CID000104802 | |
| Disease | cD177 antigen measurement | 6.71e-06 | 18 | 61 | 3 | EFO_0021866 | |
| Disease | Endemic Cretinism | 2.52e-05 | 4 | 61 | 2 | C0342200 | |
| Disease | Myxedema, Congenital | 2.52e-05 | 4 | 61 | 2 | C1578691 | |
| Disease | psychosocial stress measurement | 2.28e-04 | 11 | 61 | 2 | EFO_0006783 | |
| Disease | Congenital Hypothyroidism | 3.23e-04 | 13 | 61 | 2 | C0010308 | |
| Disease | congenital hypothyroidism (implicated_via_orthology) | 3.76e-04 | 14 | 61 | 2 | DOID:0050328 (implicated_via_orthology) | |
| Disease | acute graft vs. host disease, donor genotype effect measurement | 4.34e-04 | 15 | 61 | 2 | EFO_0004599, EFO_0007892 | |
| Disease | lumbar disc degeneration | 1.53e-03 | 28 | 61 | 2 | EFO_0004994 | |
| Disease | stimulant use measurement | 1.53e-03 | 28 | 61 | 2 | EFO_0600076 | |
| Disease | gas trapping measurement | 1.65e-03 | 29 | 61 | 2 | EFO_0007628 |
| Peptide | Gene | Start | Entry |
|---|---|---|---|
| ERYSYYTCDCDLTAF | 976 | P78357 | |
| LCVNYFFYGETVADY | 151 | Q92903 | |
| STGIYYYCDVESGRY | 236 | Q8N302 | |
| YYRIYGQACATYESA | 441 | P43155 | |
| TSRDYYFDSYAHFGI | 71 | Q9NR22 | |
| SYTCETAGYFFLYQV | 926 | O60306 | |
| GYYFCSALSNSIMYF | 111 | P01732 | |
| YNSYFSFSRNRSGYS | 66 | Q9UBZ4 | |
| ATECGSDFAYFYFVS | 1676 | Q00975 | |
| TCYDTTSDEYLRSYF | 201 | P47900 | |
| SDFSCVRYYGDSYLE | 1881 | Q5T1H1 | |
| YYYGASRRAIFDLFT | 466 | Q7RTR2 | |
| CRGYYFLRDACTYAT | 141 | P30989 | |
| STRYKFYFYAQTSAG | 1021 | Q92823 | |
| VYCSAYYIMFLGSSC | 431 | Q4VC12 | |
| ICVGVFADRAYYYGF | 1051 | Q9NRD8 | |
| GTYRCYSFSSRDPYL | 176 | Q9HCN6 | |
| AFDIYYIYGFVSASF | 221 | P51805 | |
| DAGRYVCDYTYYLSL | 121 | A6NFU8 | |
| SQDAGRYLCDFTYYT | 141 | Q9NXJ5 | |
| RYLCDFTYYTSLYQS | 146 | Q9NXJ5 | |
| GVYRYFAYDCEASFP | 161 | P07942 | |
| TFDGTYYTFLDNCTY | 4931 | P98088 | |
| VSYDYSAGYSRTAYS | 391 | A6NEQ2 | |
| FGRDFSYHYPSCDLY | 136 | Q9BSC4 | |
| VFSQRFYCGSSFYAT | 291 | Q9Y5Y3 | |
| SYGFITYRYTCDAFA | 716 | Q9UBK2 | |
| CFYYDASYRGSLLSD | 296 | Q8N6C5 | |
| YGIARFFTEYFNSVC | 41 | Q9H6J7 | |
| TLGSTISYYCEDRYY | 156 | P20851 | |
| CGNYSGAAEYLYFFR | 141 | P60228 | |
| FDYMCYYDVVLSFSS | 241 | Q9P203 | |
| GYVQQFLYTFRYFCT | 1271 | Q76NI1 | |
| FVCYYLSYYLCSGSS | 81 | Q8N0W7 | |
| LSYYLCSGSSYFVLA | 86 | Q8N0W7 | |
| YSSLAYSEAFHYSFA | 46 | Q9Y238 | |
| FTYYRSGENLYLSCF | 341 | Q00888 | |
| TAYFSSFSAYCVFRF | 181 | A6NK97 | |
| GESSFTYRAYCTEFI | 201 | Q99590 | |
| FTYYRSGEVLYLSCS | 341 | P11464 | |
| AAFAISAYASSYYRA | 586 | Q9H4L5 | |
| TAALSSYYFCIALGY | 306 | P41145 | |
| RYGYSYYNSACRISS | 141 | Q96HP8 | |
| FTYYRSGEVLYLSCS | 341 | Q9UQ74 | |
| SEFYGFSEFYYCTED | 426 | Q9Y227 | |
| YIFQLFDYYASSGIC | 446 | P48065 | |
| SYFGTFAVEFRHYRY | 206 | B9EJG8 | |
| GYVFCYRCVFHYVRS | 321 | O00623 | |
| CIYFYFAFNYRGISD | 576 | O00116 | |
| FCYRYSYQDTFLPFE | 71 | H7C241 | |
| IYSRYFFSFAANGRY | 671 | Q9UQC9 | |
| TNTYERGTYYFFDCL | 491 | Q9NZN8 | |
| YSFLEIVCVYGYSLF | 196 | Q9Y548 | |
| CGKSFSYFSYYARHQ | 166 | P17023 | |
| FDGSMYSFAGYCSYL | 46 | P04275 | |
| FSCPFFETSAAYRYY | 156 | Q92963 | |
| RSPSDSAAYFCIYTY | 106 | Q9NRA0 | |
| YVFQLFDYYAASGMC | 441 | Q9NSD5 | |
| LLRYVSYYDYFIASC | 271 | Q9NZM6 | |
| SYYDYFIASCEITFC | 276 | Q9NZM6 | |
| YLESQDSGYLYFCFR | 516 | Q8TC07 | |
| FTCASDGLTYYNRCY | 126 | Q96NZ8 | |
| RECSYCGKFFRSNYY | 471 | O75362 | |
| YLILDCSGFTFFDYS | 571 | Q8TE54 | |
| GNYLFSTSAICRYFF | 56 | P56192 | |
| TGYLSYNDIYCRFAE | 41 | O14657 |